Price
$4.87
Decreased by -0.03%
Dollar Volume (20D)
880.06 K
ADR%
9.89
Earnings Report Date (estimate)
May 9, 23 (0.36)
Market Cap.
199.79 M
Shares Float
14.92 M
Shares Outstanding
41.03 M
Beta
0.00
Price / Earnings
-4.16
BPR
20.78
20D Range
4.70 6.59
50D Range
3.52 6.67
200D Range
3.52 10.97
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
May 9, 23 -0.28
Decreased by -21.74%
-0.35
Increased by +57.14%
Mar 27, 23 -0.32
Increased by +23.81%
-0.25
Decreased by -112.00%
Nov 14, 22 -0.26
Decreased by -160.00%
-0.23
Decreased by -56.71%
Aug 15, 22 -0.25
Increased by +96.84%
-0.24
Decreased by -17.36%
May 16, 22 -0.23 -0.17
Decreased by -207.61%
Mar 28, 22 -0.42 -0.14
Decreased by -1.43 K%
Nov 15, 21 -0.10 -0.17
Increased by +242.21%
Aug 16, 21 -7.91 -4.56
Decreased by -16.11%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Mar 31, 23 0.00
Decreased by N/A%
-9.48 M
Decreased by -4.72%
Decreased by N/A%
Decreased by N/A%
Dec 31, 22 0.00
Decreased by N/A%
-13.86 M
Decreased by -67.38%
Decreased by N/A%
Decreased by N/A%
Sep 30, 22 0.00
Decreased by N/A%
-10.05 M
Decreased by -161.28%
Decreased by N/A%
Decreased by N/A%
Jun 30, 22 0.00
Decreased by N/A%
-9.89 M
Increased by +91.71%
Decreased by N/A%
Decreased by N/A%
Mar 31, 22 0.00
Decreased by N/A%
-9.05 M
Increased by +81.97%
Decreased by N/A%
Decreased by N/A%
Dec 31, 21 0.00
Decreased by -100.00%
-8.28 M
Decreased by -4.80 K%
Decreased by N/A%
Decreased by N/A%
Sep 30, 21 0.00
Decreased by -100.00%
-3.85 M
Decreased by -54.46%
Decreased by N/A%
Decreased by N/A%
Jun 30, 21 0.00
Decreased by -100.00%
-119.28 M
Decreased by -5.76 K%
Decreased by N/A%
Decreased by N/A%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.